Analysis of Efficacy of Dicycloalcohol Tablet Combined with Entecavir Capsule in the Treatment of Patients with Chronic Hepatitis B
Objective:To analyze the therapeutic effect of Dicycloalcohol Tablets combined with Entecavir Capsule in patients with chronic hepatitis B.Methods:A total of 136 patients with chronic hepatitis B treated in Xintai People's Hospital from January 2022 to October 2023 were selected as the study objects,and were divided into a control group and a study group according to random number table method,with 68 cases in each group.The control group was treated with Entecavir Capsules,and the study group was treated with Dicycloalcohol Tablets on the basis of the control group.The therapeutic effect,hepatitis B virus e antigen(HBeAg)and hepatitis B virus deoxyribonucleic acid(HBV-DNA)levels,the negative rate of HBV-DNA,liver function indexes,liver fibrosis indexes,immune function indexes and the occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 88.24%higher than 75.00%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of HBeAg and HBV-DNA in two groups were lower than before treatment,and the study group were lower than the control group,the negative rate of HBV-DNA in two groups were higher than before treatment,and the study group was higher than the control group,with statistical significances(P<0.05).After treatment,the levels of alanine aminotransferase,aspartate aminotransferase and total bilirubin in both groups were lower than before treatment,and the study group were lower than the control group,the level of albumin in both groups were higher than before treatment,and the study group was higher than the control group,the differences were statistically significant(P<0.05).After treatment,the levels of hyaluronidase,laminin,type Ⅲ procollagen and type Ⅳ collagen in the two groups were lower than before treatment,and the study group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in both groups were higher than before treatment,and the study group were higher than the control group,the level of CD8+in both groups were lower than before treatment,and study group was lower than the control group,with statistical significance(P<0.05).The incidence of adverse reactions in the study group was 14.71%,which was higher than 11.76%in the control group,but there was no significant difference between the two groups(P>0.05).Conclusion:In the treatment of chronic hepatitis B patients,Entecavir Capsule combined with Dicycloalcohol Tablets can improve the therapeutic effect and negative HBV-DNA conversion rate,reduce the levels of HBeAg and HBV-DNA,improve liver function,liver fibrosis indicators and immune function,and have good safety.
Chronic hepatitis BBicyclicalcohol tabletsEntecavirTherapeutic effectLiver functionLiver fibrosis index
国家科技期刊平台
NSTL
万方数据
